JP2016535781A - 経皮薬物送達のためのイオン性液体 - Google Patents

経皮薬物送達のためのイオン性液体 Download PDF

Info

Publication number
JP2016535781A
JP2016535781A JP2016552446A JP2016552446A JP2016535781A JP 2016535781 A JP2016535781 A JP 2016535781A JP 2016552446 A JP2016552446 A JP 2016552446A JP 2016552446 A JP2016552446 A JP 2016552446A JP 2016535781 A JP2016535781 A JP 2016535781A
Authority
JP
Japan
Prior art keywords
skin
composition
ionic liquid
drug
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016552446A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016535781A5 (enExample
Inventor
マイケル ザクレウスキー，
マイケル ザクレウスキー，
サミル ミトラゴトリ，
サミル ミトラゴトリ，
デイビッド ティー． フォックス，
デイビッド ティー． フォックス，
アンドリュー コピーシュ，
アンドリュー コピーシュ，
セスト， リコ デル
セスト， リコ デル
キャサリン ラブジョイ，
キャサリン ラブジョイ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Los Alamos National Security LLC
Original Assignee
Los Alamos National Security LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Alamos National Security LLC filed Critical Los Alamos National Security LLC
Publication of JP2016535781A publication Critical patent/JP2016535781A/ja
Publication of JP2016535781A5 publication Critical patent/JP2016535781A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
    • A01N33/02—Amines; Quaternary ammonium compounds
    • A01N33/12—Quaternary ammonium compounds
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/36—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Insects & Arthropods (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
JP2016552446A 2013-11-03 2014-11-03 経皮薬物送達のためのイオン性液体 Withdrawn JP2016535781A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361899294P 2013-11-03 2013-11-03
US61/899,294 2013-11-03
PCT/US2014/063745 WO2015066647A2 (en) 2013-11-03 2014-11-03 Ionic liquids for transdermal drug delivery

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019030302A Division JP6674058B2 (ja) 2013-11-03 2019-02-22 経皮薬物送達のためのイオン性液体

Publications (2)

Publication Number Publication Date
JP2016535781A true JP2016535781A (ja) 2016-11-17
JP2016535781A5 JP2016535781A5 (enExample) 2017-12-07

Family

ID=53005413

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016552446A Withdrawn JP2016535781A (ja) 2013-11-03 2014-11-03 経皮薬物送達のためのイオン性液体
JP2019030302A Active JP6674058B2 (ja) 2013-11-03 2019-02-22 経皮薬物送達のためのイオン性液体
JP2020037741A Withdrawn JP2020097633A (ja) 2013-11-03 2020-03-05 経皮薬物送達のためのイオン性液体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019030302A Active JP6674058B2 (ja) 2013-11-03 2019-02-22 経皮薬物送達のためのイオン性液体
JP2020037741A Withdrawn JP2020097633A (ja) 2013-11-03 2020-03-05 経皮薬物送達のためのイオン性液体

Country Status (7)

Country Link
US (3) US10449254B2 (enExample)
EP (1) EP3062819B1 (enExample)
JP (3) JP2016535781A (enExample)
KR (1) KR102286115B1 (enExample)
CA (2) CA3100536A1 (enExample)
ES (1) ES2908345T3 (enExample)
WO (1) WO2015066647A2 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019131480A (ja) * 2018-01-29 2019-08-08 旭化成株式会社 経皮吸収促進剤及び経皮製剤
JP2021503468A (ja) * 2017-11-17 2021-02-12 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 体内送達のためのイオン液体
JPWO2022091925A1 (enExample) * 2020-10-29 2022-05-05
JP2022527825A (ja) * 2019-04-03 2022-06-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 薬物送達のためのイオン液体
JP2022534293A (ja) * 2019-05-29 2022-07-28 アシスタンス ピュブリク－オピトー ドゥ パリ 緑茶カテキン共融系
JP2023503899A (ja) * 2019-11-22 2023-02-01 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 薬物送達のためのイオン液体

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2463181B (en) 2007-05-14 2013-03-27 Univ New York State Res Found Induction of a physiological dispersion response in bacterial cells in a biofilm
EP3395368A1 (en) * 2014-10-30 2018-10-31 Asahi Kasei Kabushiki Kaisha Transdermal absorption enhancer and transdermal absorption enhancement aid
CA2931913C (en) 2015-06-12 2024-03-19 Kemira Oyj Bitumen separation using ionic liquids comprising unsubstituted or substituted primary, secondary or tertiary amines, pyridines, amidines, guanidines and fatty acids and/or resin acids
WO2018044920A1 (en) 2016-08-29 2018-03-08 The Regents Of The University Of California Topical formulations based on ionic species for skin treatment
US11274137B1 (en) * 2016-10-04 2022-03-15 United States Of America As Represented By The Secretary Of The Air Force Ultra-stable protein ionic liquids
US10828265B2 (en) 2016-12-09 2020-11-10 The Regents Of The University Of California Formulations of propranolol and analogs as an amorphous melt or ionic liquid for transdermal drug delivery
WO2018222924A1 (en) 2017-06-01 2018-12-06 Arizona Board Of Regents On Behalf Of Northern Arizona University Antibiofilm formulations
AU2019239949B2 (en) * 2018-03-19 2025-06-12 Cage Bio Inc. Ionic liquid compositions for treatment of rosacea
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
KR101959524B1 (ko) * 2018-09-19 2019-03-18 주식회사 우신라보타치 리도카인을 포함한 이온토포레시스용 점착성 카타플라스마 시스템
EP3930757A1 (en) 2019-03-01 2022-01-05 President And Fellows Of Harvard College Methods and compositions for protein delivery
EP4054527A4 (en) * 2019-11-08 2023-12-06 Cage Bio Inc. TOPICAL ADMINISTRATION OF TOFACITINIB USING AN IONIC LIQUID
US20230087487A1 (en) * 2019-12-09 2023-03-23 Cage Bio, Inc. Topical delivery of rna interference agents using ionic liquid
US11684594B2 (en) 2020-05-12 2023-06-27 President And Fellows Of Harvard College Antifungal prophylaxis for cornea
US20230329988A1 (en) * 2020-06-26 2023-10-19 Cage Bio Inc. Sanitizing compositions containing ionic liquid
EP4225324A4 (en) * 2020-10-05 2024-11-13 Cage Bio Inc. IONIC LIQUID COMPOSITIONS FOR SKIN DISEASES AND CONDITIONS
KR20230105332A (ko) * 2020-11-13 2023-07-11 유니베르시다데 도 미노 공융 조성물, 방법 및 이의 용도
WO2022256291A1 (en) 2021-06-01 2022-12-08 President And Fellows Of Harvard College Hydrogel devices for drug delivery to the ear
WO2022271537A1 (en) 2021-06-25 2022-12-29 President And Fellows Of Harvard College Compositions and methods relating to injectable microemulsions
US12005134B2 (en) 2021-06-30 2024-06-11 Abe Pharmaceutical Composition for stimulating facial hair growth and methods of manufacturing a composition for stimulating facial hair growth
CA3233824A1 (en) 2021-10-08 2023-04-13 Samir Mitragotri Ionic liquids for drug delivery
WO2023086499A1 (en) 2021-11-10 2023-05-19 I2O Therapeutics, Inc. Ionic liquid compositions
CN116474153B (zh) * 2022-01-17 2024-09-27 四川大学 一种基于竹纤维-低共熔溶剂-明胶的皮肤溃疡护理贴膜
US12109303B2 (en) 2022-04-18 2024-10-08 ISHA Therapeutics LLC Orally dissolving antimicrobial film compositions and methods of their use
CN115671285B (zh) * 2022-08-24 2024-01-05 上海市皮肤病医院 一种抗真菌溶液及其制备方法和应用
WO2025147130A1 (ko) * 2024-01-03 2025-07-10 주식회사 바이온리퀴드 이온성 액체 또는 공융 용매를 이용한 신규 약물제형

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008184402A (ja) * 2007-01-29 2008-08-14 Medorekkusu:Kk 外用剤用の低刺激性溶解助剤
WO2009066457A1 (ja) * 2007-11-22 2009-05-28 Medrx Co., Ltd. 脂肪酸系イオン液体を有効成分とする外用剤組成物
WO2011056545A2 (en) * 2009-10-26 2011-05-12 Trustees Of Boston University Antimicrobial ionic liquids

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3342840A (en) * 1964-03-23 1967-09-19 Shell Oil Co Cationic ester production
US4042327A (en) 1976-01-15 1977-08-16 Waters Associates, Inc. Ion-pairing chromatography
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
JPS62209523A (ja) 1986-03-11 1987-09-14 Fuji Photo Film Co Ltd 感光材料
US4892737A (en) * 1988-09-22 1990-01-09 University Of Florida Composition and method for enhancing permeability of topical drugs
HU203372B (en) 1989-02-24 1991-07-29 Richter Gedeon Vegyeszet Process for producing hyaluronic associates and pharmaceutical compositions and cosmetics comprising such active ingredient
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5527675A (en) 1993-08-20 1996-06-18 Millipore Corporation Method for degradation and sequencing of polymers which sequentially eliminate terminal residues
DE4331012A1 (de) 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit N-Verzweigung für Therapie und Diagnostik
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
AU703926B2 (en) * 1994-03-28 1999-04-01 Trustees Of Columbia University In The City Of New York, The Composition for inactivating irritants in fluids
KR19990022598A (ko) 1995-06-07 1999-03-25 다니엘 엘. 캐시앙, 헨리 엘. 노르호프 미셀 보호 분석법
US5786571A (en) 1997-05-09 1998-07-28 Lexmark International, Inc. Wrapped temperature sensing assembly
ES2298438T3 (es) * 2001-12-21 2008-05-16 Rhodia Inc. Composiciones estables combinadas de tensioactivos cationicos y anionicos.
US7102000B2 (en) * 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US6858217B2 (en) * 2002-03-22 2005-02-22 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Stabilization of terpenoids in cosmetic compositions
EP1661560B1 (en) 2004-11-22 2008-11-05 Hisamitsu Pharmaceutical Co., Inc. Transdermal patch comprising a melting point lowering agent
US9139850B2 (en) 2005-05-19 2015-09-22 L'oreal Vectorization of dsRNA by cationic particles and topical use
US8367845B2 (en) 2006-04-21 2013-02-05 The Trustees Of Boston University Ionic viscoelastics and viscoelastic salts
WO2008031105A1 (en) 2006-09-08 2008-03-13 Delaval Holdings Ab Polymeric guanidine salt-based germicides
JP4952272B2 (ja) 2007-01-29 2012-06-13 株式会社ツムラ （ｚ）−リグスチリドの製造方法
US8247198B2 (en) 2007-09-21 2012-08-21 Friedrich Srienc Enzymatic processing in deep eutectic solvents
US8022014B2 (en) 2008-03-26 2011-09-20 Shrieve Chemical Products, Inc. Deep eutectic solvents and applications
JP5681883B2 (ja) 2009-03-27 2015-03-11 株式会社 メドレックス 核酸を有効成分とする外用剤組成物
WO2011057209A1 (en) 2009-11-06 2011-05-12 Qlt, Inc. Acidic ophthalmic formulations
CA2783351C (en) 2009-12-10 2021-09-07 Regents Of The University Of Minnesota Tal effector-mediated dna modification
ES2625847T3 (es) 2011-11-04 2017-07-20 Lipotec, S.A. Péptidos que inhiben la actividad de receptores activados y su uso en composiciones cosméticas o farmacéuticas
EP2597099B1 (en) 2011-11-23 2018-08-15 King Saud University Deep eutectic solvent and method for its preparation
EP2740484A1 (en) 2012-12-05 2014-06-11 Lipotec, S.A. Compounds useful in the treatment and/or care of the skin, hair and/or muccous membranes and their cosmetic or pharmaceutical compositions
FR3002452B1 (fr) 2013-02-28 2016-02-12 Dermaconcept Jmc Composition dermatologique antimicrobienne topique
CN105434337B (zh) 2015-04-03 2019-08-16 武汉科福新药有限责任公司 盐酸普萘洛尔亚微乳凝胶及其制备方法和用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008184402A (ja) * 2007-01-29 2008-08-14 Medorekkusu:Kk 外用剤用の低刺激性溶解助剤
WO2009066457A1 (ja) * 2007-11-22 2009-05-28 Medrx Co., Ltd. 脂肪酸系イオン液体を有効成分とする外用剤組成物
WO2011056545A2 (en) * 2009-10-26 2011-05-12 Trustees Of Boston University Antimicrobial ionic liquids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
INT. J. PHARM., vol. 441, JPN6018032229, January 2013 (2013-01-01), pages 620 - 627, ISSN: 0003863296 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7425726B2 (ja) 2017-11-17 2024-01-31 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 体内送達のためのイオン液体
JP2021503468A (ja) * 2017-11-17 2021-02-12 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 体内送達のためのイオン液体
JP2024045267A (ja) * 2017-11-17 2024-04-02 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 体内送達のためのイオン液体
JP2024045266A (ja) * 2017-11-17 2024-04-02 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 体内送達のためのイオン液体
JP2019131480A (ja) * 2018-01-29 2019-08-08 旭化成株式会社 経皮吸収促進剤及び経皮製剤
JP2022527825A (ja) * 2019-04-03 2022-06-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 薬物送達のためのイオン液体
JP2022534293A (ja) * 2019-05-29 2022-07-28 アシスタンス ピュブリク－オピトー ドゥ パリ 緑茶カテキン共融系
JP2023503899A (ja) * 2019-11-22 2023-02-01 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 薬物送達のためのイオン液体
TWI821765B (zh) * 2020-10-29 2023-11-11 日商久光製藥股份有限公司 含羅匹尼羅之貼附劑及羅匹尼羅之皮膚透過性之提升方法
JP7284877B2 (ja) 2020-10-29 2023-05-31 久光製薬株式会社 ロピニロール含有貼付剤及びロピニロールの皮膚透過性向上方法
WO2022091925A1 (ja) * 2020-10-29 2022-05-05 久光製薬株式会社 ロピニロール含有貼付剤及びロピニロールの皮膚透過性向上方法
JPWO2022091925A1 (enExample) * 2020-10-29 2022-05-05
US12440452B2 (en) 2020-10-29 2025-10-14 Hisamitsu Pharmaceutical Co., Inc. Ropinirole-containing patch and method for improving skin permeability of ropinirole

Also Published As

Publication number Publication date
CA2929630A1 (en) 2015-05-07
JP2019073561A (ja) 2019-05-16
US10449254B2 (en) 2019-10-22
ES2908345T3 (es) 2022-04-28
CA2929630C (en) 2021-01-12
WO2015066647A9 (en) 2015-09-17
WO2015066647A2 (en) 2015-05-07
JP6674058B2 (ja) 2020-04-01
EP3062819A4 (en) 2017-09-27
US20160263225A1 (en) 2016-09-15
EP3062819B1 (en) 2021-12-22
US11786597B2 (en) 2023-10-17
EP3062819A2 (en) 2016-09-07
WO2015066647A3 (en) 2015-06-18
KR102286115B1 (ko) 2021-08-04
CA3100536A1 (en) 2015-05-07
JP2020097633A (ja) 2020-06-25
US20190388545A1 (en) 2019-12-26
KR20160097202A (ko) 2016-08-17
US20240156964A1 (en) 2024-05-16

Similar Documents

Publication Publication Date Title
JP6674058B2 (ja) 経皮薬物送達のためのイオン性液体
US20210220276A1 (en) Methods of Treating Skin
ES2784307T3 (es) Besifloxacina para el tratamiento del acné resistente
EP2077106A1 (en) W/o/w emulsion composition
JP2014088453A (ja) 異なる物性の薬物の一剤形化
JP6796638B2 (ja) ヘッジホッグ阻害性化合物の送達のための局所的製剤及びその使用
JP2016155794A (ja) ナルフラフィン塩酸塩及びフィチン酸又はその塩を含有するカプセル製剤
EP3150195A1 (en) Agent for external use on skin and agent for reducing skin irritation
JP2017039694A (ja) ナルフラフィン塩酸塩含有カプセル製剤
WO2021145795A2 (ru) Биоадгезивное антибактериальное средство, способ его изготовления (варианты)
JP6008997B2 (ja) 活性剤を充填した、均一、硬質、球状のナノ多孔質リン酸カルシウム粒子の製造方法
Söpper Development of mucoadhesive carrier systems for flavoring agents and cannabidiol
TW201822768A (zh) 含４，５－環氧嗎啡喃衍生物之製劑
EP3542862A1 (en) Production method of pregabalin-containing composition and pregabalin-containing composition
US20100322978A1 (en) Medical composition
HK1170935A (en) Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171030

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180822

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190222

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190521

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20190621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190621